Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702539 | 1.00 | KMT2A (0.58) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL2168383 | 0.87 | KMT2A (0.61) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL672662 | 0.87 | KMT2A (0.61) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL29790446 | 0.87 | KMT2A (0.61) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL25834661 | 0.86 | KMT2A (0.60) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL2167853 | 0.86 | KMT2A (0.60) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL25731570 | 0.84 | GAA (0.54) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL6258804 | 0.84 | KMT2A (0.57) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL5025856 | 0.84 | KMT2A (0.57) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| 2-Phthalimidoglutaramic Acid SCHEMBL410167 | 0.84 | ALDH1A1 (0.77) | KMT2AMEN1ALDH1A1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4649963-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3131588-B1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3131588-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016197032-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| WO-2015160845-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160845-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | KMT2A 289/4885MEN1 4533/4885ALDH1A1 4348/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | KMT2A 1660/4885MEN1 1077/4885ALDH1A1 3412/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | KMT2A 584/4885MEN1 4623/4885ALDH1A1 4004/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | KMT2A 720/4885MEN1 2692/4885ALDH1A1 2101/4885 |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | KMT2A 1660/4885MEN1 1077/4885ALDH1A1 3412/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | KMT2A 605/4885MEN1 4755/4885ALDH1A1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.